Pfizer and 3SBio conclude licensing deal for SSGJ-707
Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the development, production…
All articles by
-
-
GSK’s Blenrep combos approved for multiple myeloma in EU
GSK has secured approval in the European Union (EU) for Blenrep combinations to treat adults with relapsed or refractory multiple…
-
Kling Bio and Sanofi link for antibodies and epitopes discovery
Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes. The partnership…
-
Janssen’s Darzalex new indication gains EC approval for SMM
The European Commission (EC) has approved the Johnson & Johnson company Janssen-Cilag International’s new indication for Darzalex Faspro (daratumumab) subcutaneous…
-
AstraZeneca announces $50bn US investment plans by 2030
AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). The…
-
Sanofi to acquire Vicebio’s share capital for $1.15bn upfront
Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine…
-
J&J seeks FDA approval for icotrokinra to treat psoriasis
Johnson & Johnson (J&J) has submitted a new drug application (NDA) seeking approval from the US Food and Drug Administration…
-
Biogen to invest further $2bn in North Carolina’s Research Triangle Park
Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North…
-
Sanofi concludes Blueprint Medicines acquisition
Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the expertise of a…
-
Fangzhou and Novo Nordisk link on chronic disease management
Fangzhou has signed a memorandum of understanding (MoU) with Novo Nordisk to collaborate on the management of serious chronic diseases…